NCT06414590 2026-04-14
Neoadjuvant Tebentafusp for Uveal Melanoma
Thomas Jefferson University
Phase 2 Recruiting
Clinical Trials
24 trialsNCT03025256 2026-04-02
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT05524935 2026-04-01
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06961357 2026-03-31
Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Recruiting
NCT07276386 2026-03-31
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06550674 2026-03-19
IGCMU
Centre Jean Perrin
Phase NA Recruiting
NCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting
NCT07364474 2026-03-11
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
Massachusetts General Hospital
Phase NA Recruiting
NCT04792463 2026-03-09
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
Ohio State University
Recruiting
NCT06070012 2026-02-27
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
University of Pittsburgh
Phase 2 Recruiting
NCT06627244 2026-02-23
Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
University of Miami
Phase 2 Recruiting
NCT05607095 2026-02-04
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT06121180 2025-12-04
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT06626516 2025-11-28
Tebentafusp-tebn With LDT in Metastatic UM
Thomas Jefferson University
Phase 1/2 Recruiting
NCT07203391 2025-10-02
TRIUMPH
St Vincent's Hospital, Sydney
Phase 1 Recruiting
NCT04424719 2025-09-03
SALOME
Institut Curie
Phase NA Recruiting
NCT07063875 2025-07-14
SILVER
St Vincent's Hospital, Sydney
Phase 1/2 Recruiting
NCT03467516 2025-07-10
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
University of Pittsburgh
Phase 2 Recruiting
NCT06932757 2025-06-03
Adjuvant Quisinostat in High-Risk Uveal Melanoma
University of Miami
Phase 2 Recruiting
NCT06970236 2025-05-28
IHOPE
University of Valencia
Phase NA Recruiting
NCT05502900 2025-05-15
AMUM
St. Erik Eye Hospital
Phase 3 Recruiting
NCT04729543 2023-12-04
MC2TCR
Erasmus Medical Center
Phase 1/2 Recruiting
NCT05733728 2023-05-06
Retrospective Register for Uveal Melanoma
Medical University of Vienna
Recruiting
NCT01438658 2011-09-28
UM
Hadassah Medical Organization
Recruiting